RxDoctor Payments Data

Terry Croasdale, MD

Internal Medicine · Manteca, CANPI 1295713147

Payments from drug & device makers

$467in general payments, 2019–2025

Across 24 payments — averaging $19.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$104
  • Lilly USA, LLC$50
  • Currax Pharmaceuticals LLC$50
  • GSK$44
  • Exact Sciences$34
  • AstraZeneca$33
  • plus $152 from 8 others

What the payments were for

  • Food & beverage$41789%
  • Education$5011%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$467 in reported general payments places this provider in the 65th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$236,953
Medicare patients
374
Services billed
4,606

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin178$198,717
EliquisApixaban123$146,352
JanuviaSitagliptin Phosphate70$89,589
OzempicSemaglutide55$68,521
XareltoRivaroxaban70$61,142
Trelegy ElliptaFluticasone/Umeclidin/Vilanter61$58,883
TrulicityDulaglutide42$47,960
MyrbetriqMirabegron33$36,712
Breo ElliptaFluticasone/Vilanterol60$34,004
RexultiBrexpiprazole13$31,934
JanumetSitagliptin Phos/Metformin Hcl33$24,097
FarxigaDapagliflozin Propanediol20$23,088
MounjaroTirzepatide21$21,047
Lantus SolostarInsulin Glargine,hum.Rec.Anlog71$13,944
Tresiba Flextouch U-100Insulin Degludec19$10,048

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$28$113,686103 claims
GSKTrelegy Ellipta, Breo Ellipta$44$92,887121 claims
Lilly USA, LLCTrulicity, Mounjaro$50$69,00663 claims
AstraZenecaFarxiga, Symbicort$33$32,06246 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Manteca

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →